Volume 15, Issue 1 (Volume 15, No 1 2024)                   jdc 2024, 15(1): 71-76 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Moosavi Z. Janus kinase inhibitors and malignancy. jdc 2024; 15 (1) :71-76
URL: http://jdc.tums.ac.ir/article-1-5720-en.html
Janus kinase inhibitors and malignancy
Zahrabeigom Moosavi *
Center for Research and Training in Skin Diseases and Leprosy,Tehran University of Medical Sciences, Tehran, Iran , moosavi.za@gmail.com
Abstract:   (81 Views)
Development of janus kinase inhibitors (JAKi), has significantly modified treatment of various dermatological conditions by targeting essential pathogenesis of inflammatory and autoimmune diseases. Despite therapeutic potentials of these drugs, concerns about safety appeared soon postmarketing consumption. Therefore implementing strong studies to evaluate their safety and efficacy became mandatory. Many studies have been done up to now focusing on JAKi’s serious or acceptable side effects, however, they are often retrospective or have short follow up. Due to importance of JAKi’s role in the treatment of many skin diseases, we decided to present a review on the main points of recent studies, particularly systematic reviews and clinical trials regarding serious side effects.
Keywords: jak inhibitors, malignancy, skin disease
Full-Text [PDF 197 kb]   (42 Downloads)    
Type of Study: Review | Subject: General
Received: 2024/09/17 | Accepted: 2024/05/4 | Published: 2024/05/4
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 , Tehran University of Medical Sciences, CC BY-NC 4.0

Designed & Developed by : Yektaweb